Status:
COMPLETED
Improving Emotion Regulation at the End of Breast Cancer Treatment
Lead Sponsor:
Université Libre de Bruxelles
Collaborating Sponsors:
Jules Bordet Institute
Centre de Psycho-Oncologie (CPO)
Conditions:
Breast Cancer
Emotional Disturbances
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The end of treatment marks the beginning of a challenging period for breast cancer patients. While this period often provokes a sense of relief, it can also be a source of apprehension and vulnerabili...
Detailed Description
1. Introduction At the end of treatment, breast cancer patients are confronted with the short- and long-term physical (e.g., fatigue, pain, hot flashes) and psychological (e.g., anxiety, fear of r...
Eligibility Criteria
Inclusion
- Experiencing moderate to high emotion dysregulation (one to four scores = or \> 4 on a 11-point Likert adapted Edmonton symptoms evaluation scale assessing anxiety, fear of recurrence, depression, and intrusive thoughts)
- Non-metastatic breast cancer
- Post chimiotherapy, radiotherapy, surgery treatment
- Age \> 18 years
- Completing a written informed consent
Exclusion
- Male
- Non-fluency in French
- Severe cognitive impairment
- Severe and/or acute psychiatric disorder.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03336827
Start Date
January 1 2017
End Date
February 28 2020
Last Update
December 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium, 1000